DrugPatentWatch Database Preview
Investigational Drug Information for Navitoclax
Email this page to a colleague
What is the drug development status for Navitoclax?
Navitoclax is an investigational drug.
There have been 22 clinical trials for Navitoclax.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 29th 2020.
The most common disease conditions in clinical trials are Leukemia, Lymphoid, Neoplasms, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are AbbVie, National Cancer Institute (NCI), and Genentech, Inc.
There are five hundred and sixty-three US patents protecting this investigational drug and five international patents.
Summary for Navitoclax
| US Patents | 563 |
| International Patents | 5,205 |
| US Patent Applications | 1,657 |
| WIPO Patent Applications | 1,189 |
| Japanese Patent Applications | 478 |
| Clinical Trial Progress | Phase 2 (2020-09-29) |
| Vendors | 82 |
Recent Clinical Trials for Navitoclax
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL | Hadassah Medical Center | Phase 1/Phase 2 |
| A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL | Rabin Medical Center | Phase 1/Phase 2 |
| A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL | Rambam Health Care Campus | Phase 1/Phase 2 |
Clinical Trial Summary for Navitoclax
Top disease conditions for Navitoclax
Top clinical trial sponsors for Navitoclax
US Patents for Navitoclax
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Navitoclax | ⤷ Sign up for a Free Trial | Pyrazol-3-ones that activate pro-apoptotic BAX | Dana-Farber Cancer Institute, Inc. (Boston, MA) | ⤷ Sign up for a Free Trial |
| Navitoclax | ⤷ Sign up for a Free Trial | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | Dana-Farber Cancer Institute, Inc. (Boston, MA) | ⤷ Sign up for a Free Trial |
| Navitoclax | ⤷ Sign up for a Free Trial | Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor | The Regents of the University of California (Oakland, CA) | ⤷ Sign up for a Free Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Navitoclax
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Navitoclax | Australia | AU2012322660 | 2031-10-11 | ⤷ Sign up for a Free Trial |
| Navitoclax | Australia | AU2017228527 | 2031-10-11 | ⤷ Sign up for a Free Trial |
| Navitoclax | Canada | CA2851788 | 2031-10-11 | ⤷ Sign up for a Free Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
